Implications of neocytolysis for optimal management of anaemia in chronic kidney disease

Nephron - Clinical Practice

Volumn 106, Issue 4, 2007, Pages

  Alfrey, Clarence P ^a   Fishbane, Steven ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b WINTHROP UNIVERSITY HOSPITAL   (United States)

Author keywords

Anaemia; Chronic kidney disease; Erythropoiesis stimulating agents; Neocytolysis

Indexed keywords

ALPHA5 INTEGRIN; CADHERIN; CD36 ANTIGEN; CD47 ANTIGEN; CHONDROITIN SULFATE; CHROMIUM CHLORIDE CR 51; COMPLEMENT COMPONENT C3B RECEPTOR; DECAY ACCELERATING FACTOR; ERYTHROPOIETIN; GLYCOPHORIN A; HEMOGLOBIN; HERMES ANTIGEN; OXYGEN; PHOSPHATIDYLSERINE; RECOMBINANT ERYTHROPOIETIN; VERY LATE ACTIVATION ANTIGEN 4; VON WILLEBRAND FACTOR;

ANEMIA; ARTICLE; BURST FORMING UNIT E; CELL DIFFERENTIATION; CELL LABELING; CELL MATURATION; CHRONIC KIDNEY DISEASE; CYTOLYSIS; ERYTHROCYTE FRAGILITY; ERYTHROID PRECURSOR CELL; ERYTHROPOIESIS; HEMATOCRIT; HUMAN; OXYGEN AFFINITY; PRIORITY JOURNAL; RETICULOCYTE;

ANEMIA; ERYTHROPOIESIS; ERYTHROPOIETIN; HUMANS; KIDNEY FAILURE, CHRONIC; MODELS, BIOLOGICAL; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; RISK ASSESSMENT; RISK FACTORS;

EID: 34547430009     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000104425     Document Type: Article

References (46)

1. Parker PA, Izard MW, Maher JF: Therapy of iron deficiency anemia in patients on maintenance dialysis. Nephron 1979;23:181-186.
2. Potasman I, Better OS: The role of secondary hyperparathyroidism in the anemia of chronic renal failure. Nephron 1983;33:229-231.
3. Adamson JW, Eschbach JW: Management of the anaemia of chronic renal failure with recombinant erythropoietin. Q J Med 1989;73:1093-1101.
4. Kaiser L, Schwartz KA: Aluminium-induced anemia. Am J Kidney Dis 1985;6:348-352.
5. Hampers CL, Streiff R, Nathan DG, Snyder D, Merrill JP: Megaloblastic hematopoiesis in uremia and in patients on long-term hemodialysis. N Engl J Med 1967;276:551-554.
6. Eschbach JW: The future of R-HuEPO. Nephrol Dial Transplant 1995;10(suppl 2):96-109.
7. Kausz AT, Khan SS, Abichandani R, Kazmi WH, Obrador GT, Ruthazer R, Pereira BJ: Management of patients with chronic renal insufficiency in the Northeastern United States. J Am Soc Nephrol 2001;12:1501-1507.
8. Alfrey CP, Rice L, Udden MM, Driscoll B: Neocytolysis: physiological down-regulator of red-cell mass. Lancet 1997;349:1389-1390.
9. Rice L, Alfrey CP, Driscoll T, Whitely CE, Hachey DL, Suki W: Neocytolysis contributes to the anemia of renal disease. Am J Kidney Dis 1999;33:59-62.
10. Kaufman JS, Reda DJ, Fye CL, Goldfarb DS, Henderson WG, Kleinman JG, Vaamonde CA: Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. N Engl J Med 1998;339:578-583.
11. Besarab A, Reyes CM, Hornberger J: Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002;40:439-446.
12. Berns JS, Elzein H, Lynn RI, Fishbane S, Meisels IS, Deoreo PB: Hemoglobin variability in epoetin-treated hemodialysis patients. Kidney Int 2003;64:1514-1521.
13. Lacson E Jr, Ofsthun N, Lazarus JM: Effect of variability in anemia management on hemoglobin outcomes in ESRD. Am J Kidney Dis 2003;41:111-124.
14. Collins AJ, Brenner RM, Ofman JJ, Chi EM, Stuccio-White N, Krishnan M, Solid C, Ofsthun NJ, Lazarus JM: Epoetin alfa use in patients with ESRD: an analysis of recent US prescribing patterns and hemoglobin outcomes. Am J Kidney Dis 2005;46:481-488.
15. Fishbane S, Berns JS: Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int 2005;68:1337-1343.
16. Ebben JP, Gilbertson DT, Foley RN, Collins AJ: Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations. Clin J Am Soc Nephrol 2006;1:1205-1210.
17. Fishbane S: Recombinant human erythropoietin: has treatment reached its full potential? Semin Dial 2006;19:1-4.
18. Williams WJ, Morris MW, Nelson DA: Examination of the blood; in Beutler E, Lichtman MA, Coller BS, Kipps TJ (eds): Williams' Hematology, ed 5. New York, McGraw-Hill, 1995, pp 8-15.
19. Maxwell PH, Ferguson DJ, Nicholls LG, Iredale JP, Pugh CW, Johnson MH, Ratcliffe PJ: Sites of erythropoietin production. Kidney Int 1997;51:393-401.
20. Jelkmann W: Biochemistry and assays of EPO; in Jelkmann W (ed): Erythropoietin: Molecular Biology and Clinical Use. Johnson City/TN, FP Graham Publishing, 2003, pp 35-63.
21. Maxwell P: HIF-1: an oxygen response system with special relevance to the kidney. J Am Soc Nephrol 2003;14:2712-2722.
22. Mulcahy L: The erythropoietin receptor. Semin Oncol 2001;28(suppl 8):19-23.
23. Koury MJ, Sayer ST, Brandt S: New insights into erythropoiesis. Curr Opin Hematol 2002;9:93-100.
24. Erlsev AJ, Besarab A: Erythropoietin in the pathogenesis and treatment of the anemia of chronic renal failure. Kidney Int 1997;51:622-630.
25. Polenakovic M, Sikole A: Is erythropoietin a survival factor for red blood cells? J Am Soc Nephrol 1996;7:1178-1182.
26. Koury M, Bondurant M: Erythropoietin retards DNA breakdown and prevents programmed cell death in erythroid progenitor cells. Science 1990;248:378-381.
27. Broudy VC, Lin N, Brice M, Nakamoto B, Papyannopoulo T: Erythropoietin receptor characteristics on primary human erythroid cells. Blood 1991;77:2583-2590.
28. Udden MM, Driscoll TB, Pickett MH, Leach-Huntoon CS, Alfrey CP: Decreased production of red blood cells in human subjects exposed to microgravity. J Lab Clin Med 1995;125:442-449.
29. Alfrey CP, Udden MU, Leach-Huntoon C, Driscoll T, Pickett MH: Control of the red blood cell mass in spaceflight. J Appl Physiol 1996;81:98-104.
30. Rice L, Alfrey CP: The negative regulation of red cell mass by neocytolysis: physiologic and pathophysiologic manifestations. Cell Physiol Biochem 2005;15:245-250.
31. Trial J, Rice L: Erythropoietin withdrawal leads to the destruction of young red cells at the endothelial-macrophage interface. Curr Pharm Design 2004;10:183-190.
32. Rice L, Ruiz W, Driscoll T, Whitely CE, Tapia R, Hachey DL, Gonzales GF, Alfrey CP: Neocytolysis on descent from altitude: a newly recognized mechanism for the control of red cell mass. Ann Intern Med 2001;134:652-656.
33. Trial J, Rice L, Alfrey CP: Erythropoietin withdrawal alters interactions between young red blood cells, splenic endothelial cells, and macrophages: an in vitro model of neocytolysis. J Investig Med 2001;49:335-345.
34. Halstenson CE, Macres M, Katz SA, Schneiders JR, Watanabe M, Sobota JT, Abraham PA: Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther 1991;50:702-712.
35. Macdougall IC, Gray SJ, Elston O, Breen C, Jenkins B, Browne J, Egrie J: Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 1999;10:2392-2395.
36. Besarab A, Flaharty KK, Erslev AJ, McCrea JB, Vlasses PH, Medina F, Caro J, Morris E: Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: the case for subcutaneous administration. J Am Soc Nephrol 1992;2:1405-1416.
37. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 2006;47(suppl 3):S11-S145.
38. Macdougall IC, Wilson P, Roche A: Impact of haemoglobin variability in haemodialysis patients receiving erythropoiesis-stimulating agents for the management of renal anaemia. J Am Soc Nephrol 2005;16:899A (abstr PUB541).
39. Jadoul M, Vanrenterghem Y, Foret M, Walker R, Gray SJ: Darbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patients. Nephrol Dial Transplant 2004;19:898-903.
40. Disney A: Aranesp® (darbepoetin alfa) administered once monthly (QM) maintains hemoglobin (Hb) levels in chronic kidney disease (CKD) patients. Nephrol Dial Transplant 2005;20(suppl 5):v254 (abstr MP164).
41. Ling B, Walczyk M, Agarwal A, Carrol W, Lui W, Brenner R: Darbepoetin alfa administered once monthly maintains hemoglobin concentrations in patients with chronic kidney disease. Clin Nephrol 2005;63:327-334.
42. Provenzano R, Bhaduri S, Singh AK, for the PROMPT Study Group: Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study. Clin Nephrol 2005;2:113-123.
43. Agarwal AK, Silver MR, Reed JE, Dhingra RK, Liu W, Varma N, Stehman-Breen C: An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis. J Intern Med 2006;260:577-585.
44. Dougherty FC, Reigner B, Jordan P, Pannier A: CERA (continuous erythropoiesis receptor activator): dose-response, pharmacokinetics and tolerability in phase I multiple ascending dose studies. Proc Am Soc Clin Oncol 2004;23:603 (abstr 6692).
45. Macdougall IC, Robson R, Opatrna S, Liogier X, Pannier A, Jordan P, Dougherty FC, Reigner B: Pharmacokinetics and pharmcodynamics of intravenous and subcutaneous Continuous Erythropoietin Receptor Activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol 2006;1:1211-1215.
46. Macdougall IC, Reigner B, Dougherty FC: Consistent pharmacokinetic properties of CERA (continuous erythropoietin receptor activator) in healthy volunteers and in patients with CKD. Am J Kidney Dis 2006;47:89.